P681 Impact of Crohn’s disease on survival in Korean patients with small bowel adenocarcinoma
Kim, K.(1);Choi, K.(2);Hwang, S.W.(1);Im, J.P.(2);Ye, B.D.(1);Kim, J.S.(2);Yang, S.K.(1);Koh, S.J.(2);Park, S.H.(1);
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of gastroenterology, Seoul, Korea- Republic Of;(2)Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;
In comparison with the general population, patients with Crohn’s disease (CD) are at higher risk of developing small bowel adenocarcinoma (SBA). However, with low prevalence of SBA, data regarding the impact of CD on survival are lacking. We investigated the impact of CD on survival in patients with SBA.
From January 1998 through July 2021, patients with histologically confirmed SBA were retrospectively collected and classified into binary, namely, sporadic SBA and CD-associated SBA groups. Patients with duodenal SBA were excluded. The overall survival (OS) and factors associated with survival were analysed.
Of 127 patients with SBA, 115 patients were sporadic SBA and 12 were CD-associated SBA (Table 1). Compared to patients with sporadic SBA, poorly differentiated tumour was more common among patients with CD-associated SBA (41.7 vs. 14.8%, p=0.030). Other baseline demographic characteristics including age at the diagnosis of SBA, sex, Charlson morbidity score more than 2 points, smoking history, family history of cancer, location of SBA, initial stage based on American Joint Committee on Cancer (AJCC) staging system, and treatment showed no significant difference. In survival analyses, the 1-year (yr), 2-yr, and 5-yr OS were lower in patients with CD-associated SBA, without statistical significance (1-yr OS; 81.8 vs. 90.5%, 2-yr OS; 61.4 vs. 81.7, 5-yr OS; 61.4 vs. 69.1%, p=0.590) (Fig 1). Factors associated with decreased survival were disease stage (AJCC stage IV) (hazard ratio [HR] 5.485; 95% confidence interval [CI], 2.442–12.279, p<0.001) and palliative treatment (HR 2.447; 95% CI, 1.064–5.624, p=0.035), whereas curative operation plus adjuvant chemotherapy improved survival (HR 0.335; 95% CI, 0.132–0.849, p=0.021) (Table 2). Crohn’s disease was not significantly associated with survival (HR 1.333; 95% CI, 0.472–3.769, p=0.587).
The OS of patients with CD-associated SBA was not significantly lower than that of patients with sporadic SBA. The independent risk factors for survival were the stage of SBA and type of treatment, not Crohn’s disease.